Biotech - Spark Newswire

2 minute read

Canadian Agency For Drugs And Technologies In Health Recommends Reimbursement For BioCryst’s ORLADEYO For The Routine Prevention Of Attacks In Hereditary Angioedema Patients In Canada

Today, 6:03 PM

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Canadian Agency for Drugs and Technologies in Health (CADTH) Canadian Drug Expert Committee (CDEC) has issued a positive recommendation for

BCRX

1 minute read

CEL-SCI’s Lead Head & Neck Cancer Candidate Shows 43% Survival Extension

By Vandana Singh

Today, 6:03 PM

CEL-SCI Corporation (NASDAQ:CVM) reported new data from its pivotal Phase 3 study of Multikine (Leukocyte Interleukin) in newly diagnosed locally advanced…

CVM

1 minute read

U.S. CDC Confirms It Plans To Lift Covid-19 Testing Requirements On Travelers From China

By Happy Mohamed

Today, 6:03 PM

- Reuters

FXI

1 minute read

FDA Removes Regulatory Overhang From Inhibikase Therapeutics Parkinson, Atrophy Program

By Vandana Singh

Today, 6:03 PM

The FDA lifted the full Clinical Hold on Inhibikase Therapeutics Inc’s (NASDAQ:IKT) IkT-148009, the company’s c-Abl inhibitor, in Multiple System…

IKT

1 minute read

RenovoRx’s Targeted Pancreatic Cancer Treatment Shows Positive Trend In Median Overall Survival Versus Standard Care

By Vandana Singh

Today, 6:03 PM

RNXT

2 minute read

Enanta Pharmaceuticals To Present New Data For EDP-235, Its 3CL Protease Inhibitor, In Development As An Oral, Once-Daily Treatment For COVID-19, At The 36th International Conference On Antiviral Research

By Happy Mohamed

Today, 6:03 PM

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that data for EDP-235, its lead 3CL protease

ENTA

3 minute read

AIM ImmunoTech Announces Publication Of New Analysis Of The Mechanism Of Action Of Ampligen As A Potential Prophylactic Therapy Against Ebola Virus Disease

By Happy Mohamed

Today, 6:03 PM

AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and

AIM

1 minute read

Mesoblast’s Lead Drug Candidate Goes Under FDA Priority Review For Bone Marrow Transplant Complications In Kids

By Vandana Singh

Today, 6:03 PM

Mesoblast Ltd (NASDAQ:MESO) rallied after the FDA agreed to review the company’s lead drug candidate, remestemcel-L, on a priority basis, more…

MESO

1 minute read

FDA
News

Sage Therapeutics & Biogen Reveal FDA Does Not Currently Plan To Convene Advisory Committee Meeting To Discuss NDA For Zuranolone In Treatment Of Major Depressive Disorder & Postpartum Depression

By Benzinga Newsdesk

Today, 6:03 PM

Sage Therapeutics, and Biogen announced that the U.S. Food and Drug Administration (FDA) notified the companies that the agency does not currently plan to convene an advisory committee meeting to discuss the

BIIB